|Bid||4.6875 x 0|
|Ask||4.8450 x 0|
|Day's Range||4.7515 - 4.7515|
|52 Week Range||3.2500 - 6.3000|
|Beta (3Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) GALAPAGOS NV/S ...
Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.
On Wednesday, Nov. 7, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings ...
Merrimack, which focuses on therapies for biomarker-defined cancer, said it has terminated a study dubbed SHERLOC, which evaluated its MM-121 in combination with docetaxel in patients with heregulin-positive non-small cell lung cancer, or NSCLC. Docetaxel is a chemotherapy medication used to treat several cancers, including breast cancer, head and neck cancer, prostate cancer and NSCLC.
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.